Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
May 02, 2024 06:30 ET
|
Compass Pathways; Mindful Health Solutions
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
April 29, 2024 06:30 ET
|
Compass Pathways
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024 16:01 ET
|
Compass Pathways
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
March 28, 2024 08:00 ET
|
Compass Pathways
LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
February 29, 2024 07:00 ET
|
Compass Pathways
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Highlights: COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line...
Compass Pathways to participate in upcoming TD Cowen investor conference
February 26, 2024 16:01 ET
|
Compass Pathways
LONDON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
February 22, 2024 16:01 ET
|
Compass Pathways
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways to participate in upcoming Oppenheimer investor conference
January 31, 2024 16:01 ET
|
Compass Pathways
LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
January 16, 2024 08:00 ET
|
Compass Pathways; Hackensack Meridian Health
LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
January 05, 2024 08:00 ET
|
Compass Pathways; Greenbrook TMS
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...